Ecstasy (MDMA) and high prevalence psychiatric symptomatology: somatic anxiety symptoms are associated with polydrug, not ecstasy, use
G Bedi, NT Van Dam, J Redman
JOURNAL OF PSYCHOPHARMACOLOGY | SAGE PUBLICATIONS LTD | Published : 2010
Although previous studies have examined anxiety and depression in ecstasy (+/-3,4-methylenedioxymethamphetamine; MDMA) users, it remains unclear whether symptoms are associated specifically with ecstasy or with polydrug use in general. We compared mean symptomatology and clinically significant symptoms in 45 ecstasy polydrug, 48 cannabis polydrug and 40 legal drug users, who completed standardised self-report anxiety and depression symptom measures. We further examined whether group differences were secondary to increased somatic symptom reporting, which may reflect acute/subacute drug effects. Anxiety and depression scores were higher in polydrug than legal drug users, with no difference be..View full abstract
Thanks to Lydia Windisch for practical assistance, Emeritus Professor Kim Ng for methodological consultation and Drs Jon Cole, Mitch Earleywine and Brady Reynolds for comments on this article. We also thank the participants. G. B. was supported by an Australian Postgraduate Award, and the project was funded by Monash University, School of Psychology, Psychiatry, and Psychological Medicine.